By Dean Seal
Shares of Edgewise Therapeutics advanced after the company reported positive results for its latest trial of sevasemten in patients with Becker muscular dystrophy.
The stock rose 5.4% to $29.11 early in the session. Shares have more than doubled since the start of the year.
The biopharmaceutical company said before the bell that the Phase 2 trial of its sevasemten treatment met its primary endpoint in reducing levels of creatine kinase, a marker of skeletal muscle damage.
Patients treated with sevasemten also showed stabilization in an assessment tied to the trial's secondary endpoint, the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 16, 2024 09:38 ET (14:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。